Connor, Clark & Lunn Investment Management Ltd. Gossamer Bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.98 - $1.53 $136,622 - $213,298	-139,411 Reduced 52.48%	126,233 $151,000
Q1 2023 May 09, 2023	BUY	$0.96 - $2.92 $255,018 - $775,680	265,644 New	265,644 $334,000
Q3 2022 Nov 10, 2022	BUY	$7.21 - $14.88 $462,730 - $954,983	64,179 Added 111.87%	121,546 $1.46 Million
Q2 2022 Aug 05, 2022	BUY	$5.97 - $9.97 $72,314 - $120,766	12,113 Added 26.77%	57,367 $480,000
Q1 2022 May 12, 2022	SELL	$8.44 - $12.49 $3,924 - $5,807	-465 Reduced 1.02%	45,254 $393,000
Q4 2021 Feb 10, 2022	SELL	$10.12 - $14.07 $7,964 - $11,073	-787 Reduced 1.69%	45,719 $517,000
Q3 2021 Nov 12, 2021	BUY	$7.25 - $13.23 $337,168 - $615,274	46,506 New	46,506 $585,000

Others Institutions Holding GOSS

# of Institutions

108

Shares Held

167M

Call Options Held

430K

Put Options Held

519K

Nea Management Company, LLC Timonium, MD

18.1M
Shares

$15.6 Million
1.37% of portfolio
Siren, L.L.C. New York, NY

13.3M
Shares

$11.4 Million
0.65% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$10.1 Million
0.0% of portfolio
Octagon Capital Advisors LP New York, NY

9.19M
Shares

$7.9 Million
2.2% of portfolio
Arch Venture Management, LLC Chicago, IL

8.06M
Shares

$6.93 Million
4.79% of portfolio

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $80.8M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account